Clinical trials /

Fruquintinib and Tislelizumab

Active, not recruitingPhase 2InterventionalNCT07136077 ↗

This is a Phase II trial to study control of MRD with a combination of Fruquitinib (VEGFR inhibitor) and Tislelizumab (PD-1 inhibitor) in CRC patients after adjuvant chemotherapy.

Sponsor
M.D. Anderson Cancer Center
Planned enrollment
15 participants
Start date
September 18, 2025
Primary completion
December 1, 2027 (est.)
Minimum age
18 Years
Interventions
Tislelizumab, Fruquintinib

Official title: A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

This is a Phase 2 study to determine if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have “positive” ctDNA tests for MRD.

Key Eligibility Criteria

  • Patients with confirmed microsatellite stable (MSS) stage II-IV colon adenocarcinoma
  • Patients must:
    • have completed curative intent treatments that must include 3 or more months of oxaliplatin containing chemotherapy
    • have no radiographic evidence of disease within 28 days of a positive ctDNA assay
    • have ctDNA positive assay

Treatment

Drug: Telisotuzumab, a PD-1 inhibitor

Drug: Fruquintinib, a VEGFR inhibitor

ClinicalTrials.gov ID NCT07136077

Where this trial is offered

  • MD Anderson Cancer CenterHouston, Texas

Status, sites, and study facts from ClinicalTrials.gov, last posted August 12, 2026 and refreshed here September 5, 2026.View the full record for NCT07136077.